Last reviewed 2026-04-22 · How we verify

cefoperazone sodium and sulbactam sodium

Cefoperazone sodium inhibits bacterial cell wall synthesis while sulbactam sodium protects the antibiotic from beta-lactamase degradation, together providing broad-spectrum bactericidal activity.

Cefoperazone sodium inhibits bacterial cell wall synthesis while sulbactam sodium protects the antibiotic from beta-lactamase degradation, together providing broad-spectrum bactericidal activity. Used for Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections), Polymicrobial infections including beta-lactamase-producing strains.

At a glance

Mechanism of action

Cefoperazone is a third-generation cephalosporin that binds to penicillin-binding proteins and disrupts peptidoglycan cross-linking in the bacterial cell wall. Sulbactam is a beta-lactamase inhibitor that irreversibly binds and inactivates many beta-lactamases, preventing enzymatic destruction of cefoperazone and extending its spectrum to include beta-lactamase-producing organisms. This combination is effective against gram-positive and gram-negative bacteria, including some anaerobes.

Approved indications

• Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections)
• Polymicrobial infections including beta-lactamase-producing strains

Common side effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Hypersensitivity reactions
• Elevated liver enzymes

Key clinical trials

• Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients (NA)
• Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application
• Establishment of Risk Factors Model of Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium
• Evaluate Bioequivalence of Burotam (1/1 g/Vial) (PHASE4)
• Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
• Safety and Efficacy of Vancomycin Plus Beta-lactams
• Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection (PHASE2)
• The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.